Study Status: Recruiting
Recruit Status: Recruiting
Study Type: Interventional
Official Title: A Phase I Study of BPM31510 Plus Vitamin K in Subjects With Glioblastoma That Has Recurred on a Bevacizumab-Containing Regimen
Brief Summary: This phase I trial studies the side effects and best dose of ubidecarenone injectable nanosuspension (BPM31510) in treating patients with glioblastoma or gliosarcoma that has come back and have been previously treated with bevacizumab. BPM31510 may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.